23andMe: A new two-sided data-banking market model

BMC Medical Ethics

Volumn 17, Issue 1, 2016, Pages

  Stoeklé, Henri Corto ^a,d   Mamzer Bruneel, Marie France ^a,c,d   Vogt, Guillaume ^a,b   Hervé, Christian ^a,d  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b IMAGINE INSTITUTE   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Biobanking; Data banking; Direct to consumer (DTC) genetic testing; Ethical issues; Research; Service; Two sided markets

Indexed keywords

DNA;

BIOBANK; BLOOM SYNDROME; CONFLICT OF INTEREST; ECONOMICS; ETHICS; FOOD AND DRUG ADMINISTRATION; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HUMAN; INFORMED CONSENT; LEGISLATION AND JURISPRUDENCE; MARKETING; MEDICAL RESEARCH; PRIVATE SECTOR; REPRODUCIBILITY; RISK FACTOR; UNITED STATES;

BIOLOGICAL SPECIMEN BANKS; BIOMEDICAL RESEARCH; BLOOM SYNDROME; CONFLICT OF INTEREST; DNA; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; INFORMED CONSENT; MARKETING; PRIVATE SECTOR; REPRODUCIBILITY OF RESULTS; RISK FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84966430299     PISSN: None     EISSN: 14726939     Source Type: Journal    
DOI: 10.1186/s12910-016-0101-9     Document Type: Review

References (51)

1. Stoeklé HC, Vogt G, Mamzer MF, Hervé C: Publicly available free of genetic testing and personalized medicine: discussion items. In: The new paradigm of personalized medicine or precision medicine: legal, medical and ethical issues. Paris: Dalloz edn. Edited by Dalloz; 2014: 117-128. ISBN:978-2-247-13980-4.
2. Annas GJ, Elias S. 23andMe and the FDA. N Engl J Med. 2014;370(23):2248-9.
3. Jean JS: Introduction. In: Geneticization and responsibilities. Paris: Dalloz edn.; 2008: p5-8. ISBN:978-2-247-08174-5.
4. Ku CS, Cooper DN, Polychronakos C, Naidoo N, Wu M, Soong R. Exome sequencing: dual role as a discovery and diagnostic tool. Ann Neurol. 2012;71(1):5-14.
5. Rochet JC, Tirole J. Platform competition in two-sided markets. J Eur Econ Assoc. 2003;990-1029.
6. Armstrong M. Competition in two-sided markets. Rand J Econ. 2006;37(3):668-91.
7. Weyl EG. A price theory of multi-sided platforms. Am Econ Rev. 2010;1642-1672.
8. Thornton M, Gladwin A, Payne R, Moore R, Cresswell C, McKechnie D, et al. Automation and validation of DNA-banking systems. Drug Discov Today. 2005;10(20):1369-75.
9. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409(6822):860-921.
10. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science. 2001;291(5507):1304-51.
11. Swede H, Stone CL, Norwood AR. National population-based biobanks for genetic research. Genet Med. 2007;9(3):141-9.
12. Terry SF, Terry PF. A consumer perspective on forensic DNA banking. J Law Med Ethics. 2006;34(2):408-14.
13. Fleitour G. Chromosome business. In: L'usine nouvelle, vol. N. 3235. 2011. http://www.usinenouvelle.com/article/chromosome-business.N150150.
14. Mardis ER. A decade's perspective on DNA sequencing technology. Nature. 2011;470(7333):198-203.
15. Hayden EC. Technology: The $1,000 genome. Nature. 2014;507(7492):294-5.
16. Schuster SC. Next-generation sequencing transforms today's biology. Nat Methods. 2008;5(1):16-8.
17. Meldrum C, Doyle MA, Tothill RW. Next-generation sequencing for cancer diagnostics: a practical perspective. Clin Biochem Rev. 2011;32(4):177-95.
18. Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol. 2008;26(10):1135-45.
19. Godard B, Schmidtke J, Cassiman JJ, Ayme S. Data storage and DNA banking for biomedical research: informed consent, confidentiality, quality issues, ownership, return of benefits. A professional perspective. Eur J Hum Genet. 2003;11 Suppl 2:S88-122.
20. 20. Godart B: Genomics seen by researchers and leaders from different ethno- cultural communities: limits on scientific advances in science ? In: Human, humanity and scientific progress. Paris: Dalloz edn.; 2009: 35-43. ISBN:978-2-247-08622-1.
21. Moore AD. Owning genetic information and gene enhancement techniques: why privacy and property rights may undermine social control of the human genome. Bioethics. 2000;14(2):97-119.
22. Knoppers BM, Zawati MH, Senecal K. Return of genetic testing results in the era of whole-genome sequencing. Nat Rev Genet. 2015;16(9):553-9.
23. Bauzon S: Good legal use of the genetic identity of the person In: Geneticization and responsibilities. Paris: Dalloz edn.; 2008: 121-126. ISBN:978-2-247-08174-5.
24. Rendtorff JD. Basic ethical principles in European bioethics and biolaw: autonomy, dignity, integrity and vulnerability - towards a foundation of bioethics and biolaw. Med Health Care Philos. 2002;5(3):235-44.
25. Azetsop J, Rennie S. Principlism, medical individualism, and health promotion in resource-poor countries: can autonomy-based bioethics promote social justice and population health. Philos Ethics Humanit Med. 2010;5:1.
26. Massé R. Ethics and Public Health: Challenges, values and normativity. Québec: Les Presses de l'Université Laval edn; 2003.
27. Knoppers BM. Genetic information and the family: are we our brother's keeper? Trends Biotechnol. 2002;20(2):85-6.
28. Hallowell N, Foster C, Eeles R, Ardern-Jones A, Murday V, Watson M. Balancing autonomy and responsibility: the ethics of generating and disclosing genetic information. J Med Ethics. 2003;29(2):74-9. discussion 80-73.
29. Corpas M. A family experience of personal genomics. J Genet Couns. 2012;21(3):386-91.
30. OCDE. Literacy in the Information Age: Final Report of the international survey on adult literacy. 2013.
31. Matloff E, Caplan A. Direct to confusion: lessons learned from marketing BRCA testing. Am J Bioeth. 2008;8(6):5-8.
32. Lombard Z, Baine F, Krause A, Lochan A, Macualay S, Spencer C, et al. Implications of direct-to-consumer whole-exome sequencing in South Africa. S Afr Med J. 2016;106(2):139-40.
33. Bloss CS, Wineinger NE, Darst BF, Schork NJ, Topol EJ. Impact of direct-to-consumer genomic testing at long term follow-up. J Med Genet. 2013;50(6):393-400.
34. Prainsack B. DIY Genetics: The right to know your own genome. In: Chadwick R, Levitt M, Shickle D, editors. The Right to Know and the Right Not to Know: Genetic Privacy and Responsibility. Cambridge: Cambridge University Press; 2014. p. 100-15.
35. Engber D: Who's your daddy? The perils of personal genomics. In: Slate. Science; 2013.http://www.slate.com/articles/health-and-science/science/2013/05/paternity-testing-personal-genomics-companies-will-reveal-dna-secrets.html
36. Whiting T: With genetic testing, I gave my parents the gift of divorce. In: Vox. Genetics; 2014. http://www.vox.com/2014/9/9/5975653/with-genetic-testing-i-gave-my-parents-the-gift-of-divorce-23andme
37. Kroll D: Angelina Jolie's Round Two With Mutated BRCA1: Solid Science Sprinkled With Nonsense. In: Forbes. Business. http://www.forbes.com/sites/davidkroll/2015/03/26/angelina-jolies-round-two-with-mutated-brca1-solid-science-sprinkled-with-nonsense/#2221367d737c
38. Evans DG, Barwell J, Eccles DM, Collins A, Izatt L, Jacobs C, et al. The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services. Breast Cancer Res. 2014;16(5):442.
39. Thierry JP: Biomedical ethics and legal standards. In: The new paradigm of personalized medicine or precision Medicine: legal, medical and ethical issues. Paris: Dalloz edn.; 2014: 97-116. ISBN:978-2-247-13980-4.
40. Mamzer MF, Hervé C: Requalification of research data care data: ethical and normative obstacles. In: The new paradigm of personalized medicine or precision Medicine: legal, medical and ethical issues. Paris: Dalloz edn.; 2014: 167-178. ISBN:978-2-247-13980-4.
41. Mullard A. 23andMe sets sights on UK/Canada, signs up Genentech. Nat Biotechnol. 2015;33(2):119.
42. Munro D: FDA Slaps Personal Genomics Startup 23andMe With Stiff Warning. In: Forbes. Pharma & Healthcare; 2013. http://www.forbes.com/sites/danmunro/2013/11/25/fda-slaps-personal-genomics-startup-23andme-with-stiff-warning/#7e30feee4c03
43. Dorfman R. Falling prices and unfair competition in consumer genomics. Nat Biotechnol. 2013;31(9):785-6.
44. Agence-de-Biomédecine. International legal framework in the various fields of bioethics. 2014. p. 45-9.
45. Inserm. Tests génétiques: questions scientifiques, médicales et sociétales. 2008.
46. Gibbs S: DNA-screening test 23andMe launches in UK after US ban. In: The Guardian. Technology; 2015. http://www.theguardian.com/technology/2014/dec/02/google-genetic-testing-23andme-uk-launch
47. Lemoine P. In: Finance GoEa, editor. The new grammar of success - The digital transformation of the French economy. 2014.
48. Champey Y: Genomic personalized medicine and drug treatment choices. Disclocation, perspectives. In: The new paradigm of personalized medicine or precision Medicine: legal, medical and ethical issues. Paris: Dalloz edn.; 2014: 69-76. ISBN:978-2-247-13980-4.
49. Kuhn TS. The Structure of Scientific Revolution. Chicago: University of Chicago Press; 1962.
50. Crews CW: European Commission still searching for Google monopoly. In: Forbes. Opinion; 2015. http://www.forbes.com/sites/waynecrews/2015/04/15/european-commission-still-searching-for-google-monopoly/#77e16da72dda
51. Herper M. 23andMe's Triumph - And The Long Road Ahead. In: Forbes. Pharma & Healthcare; 2015. http://www.forbes.com/sites/matthewherper/2015/10/21/23andmes-triumph-and-the-long-road-ahead/#5b61b3813498.